Firmonertinib for advanced EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted therapy called Firmonertinib for people with advanced EGFR-mutated non-small cell lung cancer. It uses a special blood test (liquid biopsy) to guide treatment and adjust it over time, aiming to make the therapy more personalized.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of EGFR mutation in your lung cancer cells.
- You should not have had any prior chemotherapy, targeted therapy, or other anti-cancer drugs for this condition.
- Your cancer must be at an advanced stage (IIIB, IIIC, or IV) that can't be treated with surgery or radiation.
- You need to be in good overall health, with a performance status score of 0 or 1 (meaning you can care for yourself and are up and about).
- You must have at least one tumor that can be measured on imaging scans.
- You should have adequate organ function (kidney, liver, and blood counts within certain limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
This trial tests a targeted pill (Firmonertinib) combined with chemotherapy before surgery for people with early to mid-stage non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination can shrink the tumor and improve outcomes.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
This trial tests whether combining an EGFR-targeting drug (furmonertinib) with either ablation or radiation therapy can help patients with early-stage lung cancer who cannot have surgery or choose not to. The goal is to see if this combination approach works better than treatment alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.